|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 203.87 USD | -2.20% |
|
-2.75% | -15.36% |
| 02:48am | Citi Downgrades ResMed to Neutral From Buy; Price Target is AU$34 | MT |
| 07-10 | Jefferies Adjusts Price Target on ResMed to $225 From $240 | MT |
Company Valuation: ResMed, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 35,903 | 30,691 | 32,133 | 28,117 | 37,762 | 29,406 | - | - |
| Change | - | -14.52% | 4.7% | -12.5% | 34.31% | -22.13% | - | - |
| Enterprise Value (EV) 1 | 36,263 | 31,192 | 33,346 | 28,585 | 37,221 | 28,557 | 27,818 | 26,952 |
| Change | - | -13.98% | 6.9% | -14.28% | 30.21% | -23.28% | -2.59% | -3.11% |
| P/E | 76.1x | 39.6x | 35.9x | 27.7x | 27.1x | 19.3x | 18.1x | 16.3x |
| PBR | 12.4x | 9.35x | 7.76x | 5.78x | 6.33x | 4.52x | 4.19x | 3.89x |
| PEG | - | 0.6x | 2.4x | 2x | 0.7x | 1.7x | 2.72x | 1.5x |
| Capitalization / Revenue | 11.2x | 8.58x | 7.61x | 6x | 7.34x | 5.2x | 4.94x | 4.62x |
| EV / Revenue | 11.3x | 8.72x | 7.9x | 6.1x | 7.23x | 5.05x | 4.67x | 4.23x |
| EV / EBITDA | 33.8x | 26.8x | 25.3x | 18.1x | 19.8x | 13x | 11.9x | 10.6x |
| EV / EBIT | 40.1x | 31.2x | 27.2x | 19.3x | 21.1x | 14x | 12.8x | 11.5x |
| EV / FCF | 57.2x | 144x | 58.1x | 22x | 22.4x | 17.5x | 16.3x | 15.2x |
| FCF Yield | 1.75% | 0.69% | 1.72% | 4.55% | 4.46% | 5.71% | 6.13% | 6.57% |
| Dividend per Share 2 | 1.56 | 1.68 | 1.8 | 1.92 | 2.12 | 2.435 | 2.634 | 2.617 |
| Rate of return | 0.63% | 0.8% | 0.82% | 1% | 0.82% | 1.19% | 1.29% | 1.28% |
| EPS 2 | 3.24 | 5.3 | 6.09 | 6.92 | 9.51 | 10.59 | 11.29 | 12.54 |
| Distribution rate | 48.1% | 31.7% | 29.6% | 27.7% | 22.3% | 23% | 23.3% | 20.9% |
| Net sales 1 | 3,197 | 3,578 | 4,223 | 4,685 | 5,146 | 5,650 | 5,955 | 6,372 |
| EBITDA 1 | 1,074 | 1,162 | 1,317 | 1,576 | 1,884 | 2,192 | 2,347 | 2,532 |
| EBIT 1 | 903.7 | 1,000 | 1,224 | 1,478 | 1,763 | 2,033 | 2,165 | 2,345 |
| Net income 1 | 474.5 | 779.4 | 897.6 | 1,021 | 1,401 | 1,548 | 1,640 | 1,823 |
| Net Debt 1 | 360.1 | 501.5 | 1,213 | 468.9 | -541.2 | -849.1 | -1,588 | -2,454 |
| Reference price 2 | 246.52 | 209.63 | 218.50 | 191.42 | 258.00 | 203.87 | 203.87 | 203.87 |
| Nbr of stocks (in thousands) | 145,640 | 146,405 | 147,062 | 146,884 | 146,365 | 144,240 | - | - |
| Announcement Date | 8/5/21 | 8/11/22 | 8/3/23 | 8/1/24 | 7/31/25 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 19.26x | 5.05x | 13.03x | 1.19% | 29.41B | |
| 26.39x | 4.75x | 18.29x | 0.35% | 196B | |
| 44.98x | 11.7x | 26.18x | -.--% | 144B | |
| 32.21x | - | - | 0.72% | 141B | |
| 16.45x | 3.42x | 11x | -.--% | 66.54B | |
| 32.88x | 7.35x | 23.38x | -.--% | 53.09B | |
| 18.34x | 2.12x | 10.96x | 2.86% | 44.12B | |
| 26.09x | 5.2x | 17.77x | 0.76% | 37.93B | |
| 45.62x | 6.37x | 19.56x | -.--% | 36.96B | |
| 14.53x | 1.62x | 9.08x | 0.24% | 29.43B | |
| Average | 27.68x | 5.29x | 16.58x | 0.61% | 77.83B | |
| Weighted average by Cap. | 30.20x | 6.21x | 18.60x | 0.47% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- RMD Stock
- Valuation ResMed, Inc.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
